Literature DB >> 12215466

P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage.

Eva Kaergel1, Dominik N Muller, Horst Honeck, Juergen Theuer, Erdenechimeg Shagdarsuren, Alexander Mullally, Friedrich C Luft, Wolf-Hagen Schunck.   

Abstract

Transgenic rats overexpressing both human renin and angiotensinogen genes (dTGR) develop hypertension, inflammation, and renal failure. We tested the hypothesis that these pathological features are associated with changes in renal P450-dependent arachidonic acid (AA) metabolism. Samples were prepared from 5- and 7-week-old dTGR and from normotensive Sprague-Dawley (SD) rats, ie, before and after the dTGR developed severe hypertension and albuminuria. At both stages, dTGR showed significantly lower renal microsomal AA epoxygenase and hydroxylase activities that reached 63% and 76% of the control values at week 7. Furthermore, the protein levels of several potential AA epoxygenases (CYP2C11, CYP2C23, and CYP2J) were significantly reduced. Immunoinhibition studies identified CYP2C23 as the major AA epoxygenase, both in dTGR and SD rats. Immunohistochemistry showed that CYP2C23 was localized in cortical and outer medullary tubules that progressively lost this enzyme from week 5 to week 7 in dTGR. CYP2C11 expression occurred only in the outer medullary tubules and was markedly reduced in dTGR compared with age-matched SD rats. These findings indicate site-specific decreases in the availability of AA epoxygenase products in the kidney of dTGR. In contrast to renal microsomes, liver microsomes of dTGR and SD rats showed no change in the expression and activity of AA epoxygenases and hydroxylases. We conclude that hypertension and end-organ damage in dTGR is associated with kidney-specific downregulation of P450-dependent AA metabolism. Because the products of AA epoxygenation have anti-inflammatory properties, this alteration may contribute to uncontrolled renal inflammation, which is a major cause of renal damage in dTGR.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215466     DOI: 10.1161/01.hyp.0000029240.44253.5e

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  18 in total

1.  Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies.

Authors:  Aleksey Nakorchevsky; Johannes A Hewel; Sunil M Kurian; Tony S Mondala; Daniel Campbell; Steve R Head; Christopher L Marsh; John R Yates; Daniel R Salomon
Journal:  J Am Soc Nephrol       Date:  2010-01-21       Impact factor: 10.121

Review 2.  Epoxyeicosatrienoic acids, hypertension, and kidney injury.

Authors:  John D Imig
Journal:  Hypertension       Date:  2015-01-12       Impact factor: 10.190

Review 3.  Epoxyeicosanoids in hypertension.

Authors:  J D Imig
Journal:  Physiol Res       Date:  2019-09-02       Impact factor: 1.881

4.  Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism.

Authors:  Katherine N Theken; Yangmei Deng; Robert N Schuck; Akinyemi Oni-Orisan; Tricia M Miller; M Alison Kannon; Samuel M Poloyac; Craig R Lee
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-12-20       Impact factor: 4.310

5.  Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}-3 fatty acids.

Authors:  Cosima Arnold; Marija Markovic; Katrin Blossey; Gerd Wallukat; Robert Fischer; Ralf Dechend; Anne Konkel; Clemens von Schacky; Friedrich C Luft; Dominik N Muller; Michael Rothe; Wolf-Hagen Schunck
Journal:  J Biol Chem       Date:  2010-08-23       Impact factor: 5.157

6.  Role of epoxyeicosatrienoic acids (EETs) in mediation of dopamine's effects in the kidney.

Authors:  Ming-Zhi Zhang; Yinqiu Wang; Bing Yao; Leslie Gewin; Shouzuo Wei; Jorge H Capdevila; Raymond C Harris
Journal:  Am J Physiol Renal Physiol       Date:  2013-10-23

7.  A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury.

Authors:  Uwe Hoff; Gordana Bubalo; Mandy Fechner; Maximilian Blum; Ye Zhu; Andreas Pohlmann; Jan Hentschel; Karen Arakelyan; Erdmann Seeliger; Bert Flemming; Dennis Gürgen; Michael Rothe; Thoralf Niendorf; Vijaya L Manthati; John R Falck; Michael Haase; Wolf-Hagen Schunck; Duska Dragun
Journal:  Acta Physiol (Oxf)       Date:  2019-06-02       Impact factor: 6.311

8.  Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats.

Authors:  Vera Certíková Chábová; Agnieszka Walkowska; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Petr Kujal; Zdenka Vernerová; Zdena Vanourková; Libor Kopkan; Herbert J Kramer; John R Falck; John D Imig; Bruce D Hammock; Ivana Vanecková; Ludek Cervenka
Journal:  Clin Sci (Lond)       Date:  2010-02-23       Impact factor: 6.124

9.  Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy.

Authors:  Md Abdul Hye Khan; Brian Fish; Geneva Wahl; Amit Sharma; John R Falck; Mahesh P Paudyal; John E Moulder; John D Imig; Eric P Cohen
Journal:  Clin Sci (Lond)       Date:  2016-01-15       Impact factor: 6.124

10.  Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity.

Authors:  Md Abdul Hye Khan; Jing Liu; Ganesh Kumar; Stephen X Skapek; John R Falck; John D Imig
Journal:  FASEB J       Date:  2013-04-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.